Online inquiry

IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12059MR)

This product GTTS-WQ12059MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12059MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ570MR IVTScrip™ mRNA-Anti-G, 62-71-3(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 62-71-3
GTTS-WQ2365MR IVTScrip™ mRNA-Anti-HGF, AMG 102(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 102
GTTS-WQ9068MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ9497MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ1301MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ11740MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MK-0646
GTTS-WQ1241MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ10062MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA L19-IL-2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW